Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...8687888990919293949596...136137»
  • ||||||||||  Clinical, Review, Journal:  Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. (Pubmed Central) -  Jun 3, 2021   
    The core clinical manifestation of MG is fatigable muscle weakness, which may affect ocular, bulbar, respiratory and limb muscles. Clinical manifestations vary according to the type of autoantibody, and whether a thymoma is present.
  • ||||||||||  Journal:  Biallelic loss of function variants in SYT2 cause a treatable congenital onset presynaptic myasthenic syndrome. (Pubmed Central) -  Jun 2, 2021   
    Treatment with an acetylcholinesterase inhibitor pursued in three patients showed clinical improvement with increased strength and function. This series further establishes SYT2 as a CMS-disease gene and expands its clinical and genetic spectrum to include recessive loss-of-function variants, manifesting as a severe congenital onset presynaptic CMS with potential treatment implications.
  • ||||||||||  Clinical, Review, Journal:  Very late onset of myasthenia gravis: case report and brief review of the literature. (Pubmed Central) -  Jun 1, 2021   
    This series further establishes SYT2 as a CMS-disease gene and expands its clinical and genetic spectrum to include recessive loss-of-function variants, manifesting as a severe congenital onset presynaptic CMS with potential treatment implications. No abstract available
  • ||||||||||  Review, Journal:  Four Athenas - Europe's first female neurosurgeons. (Pubmed Central) -  Jun 1, 2021   
    Europe's first women in neurosurgery were marked by war and adversity. Their stories carry within them a spirit of resilience, fortitude, and tenacity that continues to characterize women in neurosurgery today.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Clinical, Journal:  Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report. (Pubmed Central) -  Jun 1, 2021   
    This is, to our knowledge, the first reported case of anti-programmed cell death ligand 1-induced combination of myocarditis, myasthenia gravis, and myositis. While the use of immunologic agents has resulted in overall improved cancer outcomes, their increased use has led to a vast spectrum of immune-related adverse effects. We review the diagnostic workup and management of patients with these immune-related adverse effects, underscoring the importance of early identification given the potential for rapid deterioration.
  • ||||||||||  Review, Journal:  Association Between Myasthenia Gravis and Systemic Lupus Erythematosus as a Comorbid State. (Pubmed Central) -  Jun 1, 2021   
    It is evident from previously published data and case reports that patients with one autoimmune disease who underwent thymectomy contracted SLE and became more susceptible to other autoimmune diseases compared to the general population. Post-thymectomy follow-up of patients provides us with mechanistic clues for understanding the development of SLE-MG overlap; hence, in MG patients who have undergone thymectomy, any clinical and immune serological SLE suspicion should be carefully evaluated.
  • ||||||||||  [VIRTUAL] Anti-SOX1 encephalitis manifesting as progressive supranuclear palsy-like syndrome (Raum2) -  May 30, 2021 - Abstract #EAN2021EAN_2077;    
    Post-thymectomy follow-up of patients provides us with mechanistic clues for understanding the development of SLE-MG overlap; hence, in MG patients who have undergone thymectomy, any clinical and immune serological SLE suspicion should be carefully evaluated. Autoimmune encephalitis associated with anti-SOX1 antibodies has to be taken into consideration in the presence of rapidly progressive atypical parkinsonism with PSP-like syndrome.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    [VIRTUAL] Pembrolizumab-induced myasthenic syndrome (Raum2) -  May 30, 2021 - Abstract #EAN2021EAN_1608;    
    EPR-274 Pembrolizumab-induced myasthenic syndrome has a high mortality rate and can occur a median of four weeks after treatment. Consideration should be given prior to initiation of therapy about immunotherapy’s rare, yet serious, side effects.
  • ||||||||||  cyclosporine / Generic mfg.
    [VIRTUAL] Myasthenia gravis in Poland- healthcare burden in nationwide cohort (Room Paris) -  May 30, 2021 - Abstract #EAN2021EAN_1587;    
    Data was drawn from the National Health Fund database; MG patient was defined as a person who received at least once medical service coded with ICD-10 code MG (G70) and at least two reimbursed prescriptions for pyridostigmine bromide or ambenonium chloride in two consecutive years...66.3% received symptomatic treatment only, 33.7% – glucocorticoids (GCS) and/or other immunosuppressants (IS) – (64.6% GCS only, 17.5% – azathioprine plus GCS, 11% – azathioprine only, 4.6% – GCS plus other IS (methotrexate, mycophenolate mofetil, cyclosporine or tacrolimus), 2% – other IS only... Our findings confirm significant healthcare burden of MG, comprising a tool to plan resources needed for MG patients.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Rituximab treatment in myasthenia gravis: a serie of eight patients (Room Paris) -  May 30, 2021 - Abstract #EAN2021EAN_1584;    
    In our cohort, time from diagnosis to treatment with rituximab was quite long, and data related to long-term treatment with Rituximab is scarce in some cases. Clinical improvement must be assessed after long term treatment, and through clinical and quality of life scales.
  • ||||||||||  azathioprine / Generic mfg.
    [VIRTUAL] Very late-onset Myasthenia gravis (Room Paris) -  May 30, 2021 - Abstract #EAN2021EAN_1583;    
    As reported in the literature, ocular presentation was the commonest manifestation. Therapeutic response was very good in about half of patients, however 52.8% needed long-term immunosuppressive therapy.
  • ||||||||||  [VIRTUAL] Therapeutic successes in congenital myasthenic syndrome (CMS) (Room Paris) -  May 30, 2021 - Abstract #EAN2021EAN_1579;    
    Our case shows that pembrolizumab might be associated with Lambert-Eaton myasthenic syndrome, the optimal treatment of which is still unclear; therefore, further studies are warranted. Our cases demonstrate that even in genetically inherited disorders, small molecules can be effective if the disease is geneticaly stratified and the right therapy is administered.
  • ||||||||||  [VIRTUAL] A clinical case of Miller-Fisher syndrome after COVID-19 (Room Lisbon) -  May 30, 2021 - Abstract #EAN2021EAN_1264;    
    Patient was successfully treated with Immunoglobulin G (35g per day for five days) with complete symptoms regression. Differential diagnosis with stroke, myasthenia gravis, other demyelinating disease was performed.
  • ||||||||||  [VIRTUAL] Neurological manifestations in patients with COVID-19: a Tunisian study (Room Oslo) -  May 30, 2021 - Abstract #EAN2021EAN_1188;    
    Differential diagnosis with stroke, myasthenia gravis, other demyelinating disease was performed. In the current pandemic context, physicians should be aware of the broad spectrum of neurological signs of COVID-19 for early diagnosis and management of patients.
  • ||||||||||  [VIRTUAL] An Italian patient with Amyotrophic Lateral Sclerosis and Myasthenia Gravis: a clue for the dying-back hypothesis (Main Auditorium) -  May 30, 2021 - Abstract #EAN2021EAN_1137;    
    The results suggest that the patient, known for suffering from MG, developed also ALS. The presence of SOX1 antibodies, known to cause neuromuscular junction diseases, may support the role of dysimmunity in pathogenesis of motor neuron diseases, underlying the fact that muscles and neuromuscular junctions may be sites of disease manifestation in early stage of ALS, supporting what is called the “dying-back” hypothesis.
  • ||||||||||  efgartigimod IV (ARGX-113 IV) / argenx, Broteio
    [VIRTUAL] Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: phase 3 adapt study results (Room Istanbul) -  May 30, 2021 - Abstract #EAN2021EAN_1078;    
    The presence of SOX1 antibodies, known to cause neuromuscular junction diseases, may support the role of dysimmunity in pathogenesis of motor neuron diseases, underlying the fact that muscles and neuromuscular junctions may be sites of disease manifestation in early stage of ALS, supporting what is called the “dying-back” hypothesis. Efgartigimod was well tolerated and clinically efficacious in patients with gMG.
  • ||||||||||  [VIRTUAL] Distal Presenting Myasthenia Gravis – Eletrophysiologic Tests Role (Room Paris) -  May 30, 2021 - Abstract #EAN2021EAN_992;    
    Positive anti-SOX1 antibodies suggests the existence of a SCLC, reinforcing the need for a histological diagnosis to proceed treatment. Even though the history of ocular disturbances in first case and the proximal and axial limb involvement in both could have pointed to MG, the prominent distal weakness could have been misleading, so we conclude that neurophysiological studies were crucial to a timely and accurate diagnosis.
  • ||||||||||  zeteletinib (BOS-172738) / Boston Pharma
    [VIRTUAL] Lambert-Eaton-Myasthenic-Syndrome as an adverse effect of RET inhibitor therapy: a case report (Room Paris) -  May 30, 2021 - Abstract #EAN2021EAN_990;    
    As far as we know, this is the first described case suggesting an association between RET inhibitor therapy, a novel treatment for advanced tumors with RET gene alterations, and LEMS. Physicians should be aware of this possible adverse effect in patients who develop muscle weakness while undergoing RET inhibitor therapy.
  • ||||||||||  [VIRTUAL] Long-term outcome in patients with myasthenia gravis (Room Paris) -  May 30, 2021 - Abstract #EAN2021EAN_985;    
    Although after ten years majority of MG patients were in remission, their QoL was still reduced. Neurologists should be aware that poor QoL may persist even if MG is well treated.
  • ||||||||||  [VIRTUAL] Diagnosis of DOK7 Congenital Myasthenic Syndrome during pregnancy (Room Paris) -  May 30, 2021 - Abstract #EAN2021EAN_970;    
    We performed a literature review regarding pregnancy and CMS, particularly due to DOK7 mutations, and based on our observations, pregnancy might be a risk factor for clinical onset or worsening of symptoms in DOK7 CMS patients. We recommend that patients of child-bearing potential diagnosed with CMS, particularly due to DOK7 mutations, should be counseled in advance and closely followed during pregnancy and postpartum period, through a multidisciplinary approach for optimal clinical control and avoid maternal and fetal adverse outcomes.
  • ||||||||||  Review, Journal:  Economic Costs of Myasthenia Gravis: A Systematic Review. (Pubmed Central) -  May 29, 2021   
    We show that the current body of literature of costs of MG is sparse, limited to a few geographical settings and resource categories, mostly dated, and subject to non-trivial variability, both within and between countries. Our synthesis will help researchers and decision-makers identify gaps in the local health economic context of MG and inform future cost studies and economic evaluations in this patient population.